chrisvoncsefalvay/vaers-outcomes huggingface dataset:
extra dose administered; Diagnosed with shingles (on Scalp) / receive both the Shingrix Vaccine and the earlier Shingles Vaccine; Diagnosed with shingles (on Scalp) / receive both the Shingrix Vaccine and the earlier Shingles Vaccine; This case was reported by a consumer via other manufacturer and described the occurrence of vaccination failure in a 70-year-old female patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis and Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included allergic reaction to analgesics, allergy to topical drugs, reaction to drug preservatives and perfume sensitivity. Concomitant products included atorvastatin calcium (Lipitor), acetylsalicylic acid (Aspirin) and fexofenadine hydrochloride (Allegra).   On an unknown date, the patient received the 1st dose of Shingles vaccine, the 2nd dose of Shingrix and the 3rd dose of Shingrix. On 3rd February 2021, unknown after receiving Shingles vaccine, Shingrix and Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the patient experienced extra dose administered. On an unknown date, the outcome of the vaccination failure, shingles and extra dose administered were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine, Shingrix and Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received 2 doses of Shingrix and experienced shingles. This case was considered as suspected vaccination failure as details regarding vaccination schedule, time to onset for target disease and laboratory confirmation were unknown at the time of reporting. The patient received extra dose of Shingrix, which led to extra dose administered.
This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On an unknown date, the patient was vaccinated with improperly stored dose of PNEUMOVAX 23 (lot # R006466, expiration date: 24-OCT-2019, dose and route of administration were not provided) for prophylaxis. Administered dose of PNEUMOVAX 23 experienced multiple temperature excursion between 47 to 77 Fahrenheit degrees (reported also as 49.1 Fahrenheit degrees) for 40 hours and 30 minutes. No previous temperature excursion was reported. Digital data logger was involved. This is one of two reports received from the same reporter. Sender's Comments: US-009507513-1812USA006419.
Woke up with a swollen and sore spot under my left arm. Throughout the day, the soreness moved and affected the outside of my wrist (from my pinkie) up the inside of my arm, armpit, left chest, breast and around to the left side of my upper back. I went to the doctor 6 days after the vaccination and  was told I had swollen lymph nodes under my left arm and that the effects could last 2 weeks. I also have a rash on my left arm. The pain is dull and feels like a bad sunburn. There is numbness in the area of the rash. I was told to take Ibuprofen for the pain, which is constant.
Extreme fatigue, restless sleep, headache, digestive problems,  eye and visual problems, skin irritation, sore throat
Invalid second dose do to leaking syringe; This spontaneous case was reported by a nurse and describes the occurrence of ACCIDENTAL UNDERDOSE (Invalid second dose do to leaking syringe) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 24-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Jun-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced ACCIDENTAL UNDERDOSE (Invalid second dose do to leaking syringe). At the time of the report, ACCIDENTAL UNDERDOSE (Invalid second dose do to leaking syringe) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant product use was provided by the reporter.  No treatment medication was provided.  The patient received a invalid second dose do to leaking syringe. A partial second dose was then administered.  Action taken with mRNA-1273 in response to the event was not applicable.
Pain to arm radiating throughout the arm causing limitation in range of motion with weakness. Reported to Occupational Health (OHD) on 10/12/2016. Requesting to continue palliative measures and declined physician evaluation at this time.
Round rash approx. 2 inches across at injection site. Area is hot and itchy and hard. Did not notice until today. Looks similar to a large hive.
Information has been received from a physician via a company representative concerning a female patient of unknown age. The patient's concurrent conditions, medical histories and concomitant therapies were not reported. On an unknown date in July 2016 (reported as "two months ago"), the patient was vaccinated with the first dose of GARDASIL 9 (lot #, expiration date and dose were unknown), intramuscularly. On an unknown date in 2016 (reported as "eleven days after the GARDASIL 9 was administered"), the patient experienced a headache which was turned out to be a chronic headache. Because the patient was still experiencing the chronic headache, the patient's mother explained that the patient would not receive the second or third dose of GARDASIL 9 series. At the time of reporting, the patient did not recovered and was still experiencing the chronic headache. The patient did not seek medical attention. No product quality complaint (PQC) was involved. The causal relationship between the event and GARDASIL 9 was not provided. Additional information has been requested.
All day 3/9/2022 I had a burning in my nose, stuffy throat.  Over the day, I developed a cough and lost smell and taste.  Tested with an At Home COVID-19 test, positive.  Saw Doctor 3/13 who ordered a CAT scan of lungs, this is still being scheduled.  Symptoms had been diminishing and were gone by 3/21, except a cough that lingers to time of reporting.
Patient experienced syncope after receiving 2nd Pfizer Covid-19 vaccine. He sat in the waiting area for approximately 2 minutes before coming back and knocking on the consult room door. When we opened the door he said he felt like he was going to pass out and then fell to the floor, hitting the left side of his head against the wall. He quickly regained consciousness after only a second or two and was able to scoot into the consultation room where we had him lie on his back and elevate his legs. We also gave him a cold compress for his head. We paged department and when AP arrived he contacted EMS to come check him over. The patient did not loose consciousness again and was able to hold a conversation with us while waiting. EMS arrived and checked his vitals and came to the conclusion that he did not need an ambulance. After EMS left the patient drank water and orange juice and sat in the consultation room with me for 20 more minutes before leaving. Patient has no previous history of vaccine reactions or history of fainting. He had no reactions to his first dose other than a sore arm.
p/ pt recv vax in 7/96 pt in 4/98 devel varicella. pt seen by MD @ end of course w/well healed crusted lesions
pt recv vax 29MAY97 & w/in 24hr exp bruising, numbness, & tingling radiating down the lt arm for 3wk;
Pt started running a fever on 9/10/01 after shot was given. She was given Tylenol and Motrin 1 tsp. Fever had lasted until the present.
Pt completed series of vax AUG89; Lab eval in JAN90 revealed GGT 57, SGOT 46, SGPT 101, & Serum Bilirubin normal; MAY90 LDH 729; ultrasound rt upper quad inc showed attenuation poss fatty infiltration;
This spontaneous report was received from a female licensed practical nurse of unknown age reporting on herself, who on unknown dates was vaccinated with the full childhood vaccination series of RECOMBIVAX HB or Hepatitis C vaccine (manufacturer unknown) (route, lot numbers and expiration date were not provided). No suspect or concomitant medications were reported. The licensed practical nurse reported that on an unknown date (reported as recently), she had a titer done for Hepatitis B, and the Hepatitis B titer test was negative or low, even though she had completed the full childhood vaccination series of Hepatitis B vaccine (manufacturer unknown, but RECOMBIVAX HB could not be ruled out at the time of the call). The nurse reported that a decision was made to administered three more doses of RECOMBIVAX HB and then repeat the test. About a week ago, on approximately on 26-MAR-2014, she received a dose pediatric RECOMBIVAX HB (0.5 ml dose) rather than the adult dose (no product confusion discovered, just a medication error; no adverse events reported). The nurse also reported that she had a needle stick (unspecified date and unspecified product involved). At the time of the report, outcome of hepatitis test was negative or low was unknown. Additional information is not expected.
Following my second dose of the Pfizer Covid-19 vaccine in late January, I missed my period in the month of February.  I should note that my husband has had a vasectomy and I am not sexually active with anyone but him so pregnancy was not a possible reason for a missed period.  In addition, I have never missed a period unless I have been pregnant and I am textbook regular with a normal 26 day cycle.  I then had a 20 day period in March.  It stopped only because I went to my gynecologist who ordered an ultrasound, during which it was found that the lining of my uterus was extra thick.  He scraped the lining of my uterus in order to stop the bleeding and did a biopsy at that time, which turned up negative two days later.   After this extra long period, I began having bloating, weight gain, loss of strength, and other estrogen dominant type symptoms.  Only in early August of this year 2021 did my body go back to normal.  I should note that nothing about my eating or workout habits had changed.  I exercise 6 days per week and eat extremely clean.  When I asked my gynecologist if I could be going through early menopause, he said that I was not in menopause.  My mother was 51 years old when she began menopause.
6-CM erythema, warm to touch @ inject site; Fever of 102F;
14Nov89, 12Dec89, 09May90 pt vax w/ hepta B; 18Jun90 titer indicated non responder.  27Jun, 14Aug, 1990 recv booster vax .  Titer indicated non responder.
this is one of two pt from this site to recv a vax & devel an inj site rxn characterized by swelling & tenderness;
Rash at injection site app 1? x 22? about 3 hours after injection; 24 hours later rash was 2? x 3.5? & warm to touch; 48 hrs rash is 3? wide x 6? long and still slightly warm to touch and a bit itchy.. Other than increased tiredness and very minor headache, no other symptoms. Confirmed at Dr office with advice to watch and go to Urgent Care if symptoms worsen.
Heat, swelling, redness and pain at injection site;  body aches & fatigue despite taking NSAID.   2 days so far unable to perform activities of daily living
pt recv vax 22OCT96 12PM;6PM pt was vomiting & pain in lt upper abd;12MN pain worst-MD met pt @ ER pt had abn EKG, elevated WBC, elevated BP, CXR abn;
after my bowel movement, there was a lot of dark red blood in my stool and in the toilet. It then turned to bright red blood my next few bowel movements.; This is a spontaneous report from a contactable consumer (patient). A 38-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration at the age of 38-year-old administered in arm right on 13May2021 18:30 (Lot Number: ER8736) as 1ST DOSE, SINGLE for covid-19 immunisation. Medical history included hypertension and not on meds currently. The patient's concomitant medications were not reported. It is reported the patient has a regular bowel movement between 3:30 am and 5:30 am every morning. The patient received the 1st dose on the COVID-19 vaccine on Thursday evening (13May2021) at 6:30 pm and on Saturday morning (15May2021) 05:00, after her bowel movement, there was a lot of dark red blood in her stool and in the toilet. It then turned to bright red blood of next few bowel movements. There was no pain or cramping. The bleeding during the bowel movements lasted intermittently 3-4 days and then stopped. The patient had not had blood in her stool since then, but she was due for her next vaccine tomorrow evening.  She also has a history of hypertension. After the 3rd day, she did reach out to a Telehealth physician who advised to go to an urgent care. She made an appointment for the next day, but the bleeding appeared to have stopped. No treatment received for the event. The outcome of the event was recovered on 19May2021. The patient is not pregnant.
Developed DVT right femoral, popliteal, calf veins, onset of symptoms 9/12/22, diagnosed 9/15/22 by ultrasound at a local hospital.
High fever; Headache; Vomiting; This is a spontaneous report from a contactable nurse via Pfizer Sales Representative. This Nurse reported similar events for 4 patients. This is report 3 of 4. This Nurse reported that a 16-year-old patient received meningococcal group b rlp2086 (TRUMENBA), intramuscular in arm on unspecified date at single dose for meningitis serogroup B vaccine, and meningococcal vaccine a/c/y/w conj (dip tox) (MENACTRA, injection), intramuscular in arm on unspecified date at unknown dosage for vaccine. The patient was administered Trumenba injection in one arm and Menactra injection in the other arm at the same time. The patient medical history and concomitant medications were not reported. The patient experienced high fever, headache, and vomiting on an unspecified date. Outcome of events was unknown.   No follow-up attempts are needed. Information about lot/batch number cannot be obtained.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2020279270 Same reporter,drug,event/Different patient
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. Medical assistant reported that the patient was inadvertently given a 3rd dose of VARIVAX (Merck). Concomitant medications were not reported. No adverse effect reported. Follow up information has been received from the medical assistant refers to a 12 year old male patient with deficient on several immunizations. The history drugs included Hepatitis B vaccine, Hepatitis A vaccine, HPV vaccine and MENACTRA vaccine. The lab included height was 4 feet 9 inches. Temperature was 93.1. Blood pressure was 98/52. Temperature was 98.5. Pulse was 78. Respirations were 16. General: No apparent distress. He was alert. He was talkative. Head was normocephalic and atraumatic. Eyes: Without icterus or drainage. Heart: Tones were regular. Lungs: Sounds revealed faint wheeze. Abdomen: Soft and nontender. Extremities: No cyanosis or edema. On 22-JUL-2013 the patient was vaccinated with VARIVAX (Merck) (lot # H017133, dose 3, subcutaneous in the left arm). On an unknown date the patient experienced arm were swelling and arm were sore/tender. The outcome of the adverse events was unknown. Additional information is not expected.
A sore arm for a couple of days; Arm became very red; Swollen; Eruption on her arm started 12 days after receiving vaccine; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE RASH (Eruption on her arm started 12 days after receiving vaccine), VACCINATION SITE ERYTHEMA (Arm became very red), VACCINATION SITE SWELLING (Swollen) and VACCINATION SITE PAIN (A sore arm for a couple of days) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011j20a) for COVID-19 vaccination.     The patient's past medical history included Cancer. Concomitant products included PREDNISONE and CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for an unknown indication.    On 23-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Jan-2021, the patient experienced VACCINATION SITE RASH (Eruption on her arm started 12 days after receiving vaccine). On 09-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Arm became very red) and VACCINATION SITE SWELLING (Swollen). On an unknown date, the patient experienced VACCINATION SITE PAIN (A sore arm for a couple of days). At the time of the report, VACCINATION SITE RASH (Eruption on her arm started 12 days after receiving vaccine), VACCINATION SITE ERYTHEMA (Arm became very red), VACCINATION SITE SWELLING (Swollen) and VACCINATION SITE PAIN (A sore arm for a couple of days) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient hasrecieved chemotherapy and immunotherapy in the past.  Treatment medication included a topical cream.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event,s a causal relationship cannot be excluded.
Died 3 months after injection of coronary heart attack. Had no shortness of breath/ tiredness or normal signs of someone w 90 percent blockage and had passed a physical and 5 lifeline screenings in June with no concerns.
My skin symptoms started with red bumpy rash on my abdomen. The front of my abdomen and sides and didn't notice it anywhere else. I treated it myself with clindamycin liquid. That's what was given me to treat skin problems in the past. I used that and it cleared up pretty quickly within a couple weeks. I also happened to have extremely red itchy eyes that were matted in the morning and goopy during the day. I treated that with a warm moist compress. I used a hypochlorous acid to clean my eye lids, OTC lid and lash cleanser that my doctor had recommended. The facial symptoms started towards the end of February 2022. Again red spots on my face that gradually increased and each day there would be an additional accumulation of red spots. they didn't itch and they weren't really annoying. some of them were papular so I tried to use the clindamycin on those and really kept getting more and more on my face and are going down my neck on each side of my throat and the back of my neck as well. general itchiness all over body, but there was no rash in other places. scalp was really itchy as well, but not on my face. Another odd symptom I had was- I did have a PCR test and my left nostril internally did not heal well. I had some bleeding with that and it is just now finally getting better. as my face started to get better, the inside of my nose also started to get better. it just happened to be the PCR test irritated it. I'm unsure. One more thing to mention, I've noticed an increase in migraines, even with the first and second dose. and Since the booster, I've had to use my migraine medication more frequently. I saw the dermatologist for the facial breakout on March 14, 2022. She gave me another cleanser to use, FINACEA 15% foam and recommended that I use that twice daily. It would cause some burning and stinging which it did... but it definitely helps whatever the rash was to go away. she thought it was Rosacea which I have not had before. I had my follow up with her yesterday and she recommended to continue to using this cleanser twice a day, but my face is clear now- the way it used to be.
At @ 3 am on 1/21/21  , I awakened with sternal pain  and numbness in my left hand.  The episode was brief .  I took one Tums and an 81 mg aspirin .   The pain resolved .
He cant seem to get his sugar under control; Blood sugar started to rise ever since vaccine; Insulin is not as effective as it used to be prior to taken the Moderna vaccine; A spontaneous report was received from a consumer (patient), elderly male patient of unknown age, unknown race and ethnicity, who received Moderna's COVID-19 vaccine (mRNA-1273), and experienced, blood sugar started to rise ever since vaccine (hyperglycaemia), he can't seem to get his sugar under control (diabetes mellitus inadequate control), and insulin is not as effective as it used to be prior to taken the Moderna vaccine (drug interaction).  The patient's current condition included diabetic. There was no medical history reported. Concomitant medication reported included are insulin.  On an unknown date, few weeks ago prior to the onset of events, the patient received their first of planned doses of mRNA-1273 (batch number: unknown), intramuscular for the prophylaxis of COVID-19 infection.  On an unknown date, three to four days later, after administering COVID-19 vaccine, the patient's blood sugar level started to rise ever since the vaccine was given. The patient's blood sugar can't seem to get down under control which was assessed as medically significant. The patient feels that the insulin was not as effective as it used to be prior to taken the Moderna vaccine. No treatment medication information was provided.  Action taken with second dose of mRNA-1273 in response to the events was not reported.   The outcome of the events, blood sugar started to rise ever since vaccine, he can't seem to get his sugar under control, and insulin is not as effective as it used to be prior to taken the Moderna vaccine, were not reported.; Reporter's Comments: Very limited information regarding the events has been provided at this time. Further information has been requested.
Patient was given a 3rd dose of Pfizer 33 days after his 2nd dose. Per the State, the dose is considered invalid. Attempted to contact patient to inform of the vaccine adminstration error, unable to get ahold of the patient. Left detailed message requesiting a call back.
Information has been received from a physician concerning a 5 year old female with allergy to AMOXICILLIN (hives) and allergy to sulfa who on 28-APR-2009 was vaccinated at the privet doctor's office/hospital with a second dose of VARIVAX (Merck) (Lot # 663705/0331Y), subcutaneously into the left thigh and the fifth dose of DTAP (Lot # AC20B14CB), IM into the left thigh.  Concomitant therapy included vitamins (unspecified).  On 30-APR-2009 the patient developed erythematous rash that measured 7.5cm X 12 cm at left thigh injection site.  At the time of the reporting, the outcome of the event was unknown.  No further information is available.
Patient came to our pharmacy 3 days after vaccine administration. Her left arm had small, flat, red spots down her forearm and up to her deltoid. She stated they were not painful or itchy.
Headache, chills at 14 hours...redness and swelling at injection site started at two days. Redness increasing,